The device is designed to expand as children grow, potentially reducing the need for repeat open-heart surgeries in pediatric patients with congenital valve dis

The expanded label moves Eli Lilly's BTK inhibitor into untreated chronic lymphocytic leukemia and small lymphocytic lymphoma patients, widening its earlier rel

The deal expands Novo's oral obesity pipeline beyond its own candidates amid intensifying competition with Eli Lilly in the GLP-1 market.

The mandatory model extends most-favored-nation style price benchmarking to physician-administered drugs, a significant shift in US drug pricing policy.

The decision removes one of the larger pharma entrants from the oral obesity race and reflects the difficulty of catching Lilly and Novo.

The filing follows Phase 3 REZILIENT3 results and targets an EGFR exon 20 insertion subset with limited first-line options.

The advisory panel's favorable vote moves GRAIL's multi-cancer early detection blood test closer to US regulatory clearance.

Cardiovascular outcomes data could strengthen Foundayo's case as payers and regulators scrutinize GLP-1 class benefits beyond weight loss.

The investment is part of Lilly's multi-billion-dollar manufacturing buildout to meet demand for its GLP-1 medicines.

The mid-stage data points to a broader metabolic benefit beyond weight loss for the dual agonist, which is being developed for obesity-related conditions.

The narrow scope of the rule limits its near-term revenue impact relative to earlier expectations for broad most-favored-nation pricing.

The results add another contender to the crowded obesity drug field as Boehringer pushes its glucagon/GLP-1 dual agonist toward late-stage development.

The savings estimate frames the administration's pricing agreement as a fiscal win while drugmakers navigate the new terms.

The tracker tracks the fast-moving oral GLP-1 race, where Lilly's oral candidate is gaining on Novo's rival pill in market momentum.

The event put GLP-1 pricing at the center of the administration's drug cost agenda, with implications for Medicare coverage of obesity medicines.

The growth underscores how GLP-1 obesity medicines have become the primary revenue engine for large-cap pharma.

The delay ties a regulatory decision on the hemophilia candidate to manufacturing site fixes, a recurring issue for Novo's production network.

The readout is a key test for in vivo CRISPR editing as Intellia moves its lead program toward regulatory submission.